ClinicalTrials.gg
RecruitingNCT04776473FIACUpdated May 16, 2023

Treatment of Intra-articular Fractures of the Mandibular Condyle

An interventional study of Open treatment and Closed treatment in Intra-articular Fracture of the Mandibular Condyle, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 7 sites in France. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Study summary

Intra-articular fractures of the mandibular condyle ((IAFC) are usually treated by means of physical therapy with or without transient maxillo-mandibular fixation (conservative or closed treatment). However, this can lead to incomplete manducatory function recovery due to limited mandibular mobility. During the last 15 years, a growing interest has emerged for open (surgical) treatment of these fractures. Although there is more and more evidence suggesting that the open treatment may be the treatment of choice for selected cases of subcondylar fractures, the best option remains controversial for high condylar fractures.

The primary objective of the trial is to compare mandibular mobility at 3 months post-treatment between open (surgical) and closed (conservative) treatment of intra-articular fracture (high fracture) of the mandibular condyle.

This study is an open multicenter randomized controlled trial with 2 parallel arms. Eligible patients will be randomized 1 :1 between open and closed-treatment group.

Read the detailed description

The mandibular condyle is one of the most frequent locations of facial fractures. It can lead to severe functional impairment if the occlusion is not properly restored and the mandibular mobility not recovered totally or within an acceptable range. Most frequent sequels of these fractures include limitation of mandibular movements resulting in limited mouth opening, occlusal disturbance causing chewing malfunction, chronic pain, chronic temporo-mandibular joint (TMJ) disorder and facial asymmetry. The risk of permanent limited mouth opening is even higher when the fracture is located inside the TMJ. Although the superiority of surgical treatment is now widely accepted for low-level fractures of the condylar unit (i.e., extra-articular fractures) the treatment of fractures involving the TMJ in adult patients is still controversial.

Treatment principles in these fractures can be ranked in two groups: closed and open treatments. Closed treatment - also called closed reduction or conservative treatment - consists in prolonged physical therapy frequently associated with transient maxillo-mandibular fixation (MMF). Open treatment consists in open reduction and internal fixation of the fracture (ORIF).

No randomized controlled trial has ever evaluated the superiority of open versus closed treatment, and treatment strategy for IAFC remains a matter of ongoing debate.

The primary objective of this trial is to compare mandibular mobility at 3 months post-treatment between open (surgical) and closed (conservative) treatment of intra-articular fracture (high fracture) of the mandibular condyle.

The secondary objectives are to compare between open (surgical) and closed (conservative) treatments:

At 3 weeks, 6 weeks, 3 months, 6 months, and 12 months post-treatment:

  • maximal mouth opening (in mm)
  • maximal mandibular protrusion (in mm),
  • maximal lateral excursion (in mm),
  • lateral deviation of the mandible during mouth opening
  • occlusal disturbance evaluated by both the patient and the surgeon
  • pain using a visual analog scale
  • subjective functional impairment as assessed by the Mandibular Function Impairment Questionnaire

Overall:

  • duration of sick leave
  • time to normal activity recovery (social activities, eating, sports) We will also evaluate compliance with the intervention. This trial is an open multicenter randomized controlled trial with 2 parallel arms. Eligible patients will be randomized 1 :1 between open and closed-treatment group.
02

Conditions studied

  • Intra-articular Fracture of the Mandibular Condyle

Keywords

  • intra-articular fracture
  • mandibular condyle
  • surgical treatment
  • conservative treatment
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (≥18 y-o) \< 85 years
  2. Displaced non-comminuted intra-articular fracture of the mandibular condyle (IAFC) as defined by a fracture line above a horizontal line tangent to the mandibular notch
  3. Objectifiable induced malocclusion and/or ramus shortening ≥2 mm on CT-scan (a ramus shortening ≥2 mm on CT-scan is necessary in case of other associated mandibular or occluso-facial fractures)
  4. Unilateral or bilateral fracture
  5. Isolated or associated with other facial / extra-facial skeleton / dental / soft tissue lesions
  6. Treatment within 14 days post trauma
  7. Affiliation to a social security regime (excepted AME)
  8. Written

Exclusion criteria

Exclusion Criteria:

  1. to surgical treatment (for any medical or anatomical reason, like comminuted fracture for instance)
  2. Major teeth loss or edentulous patient (occlusion impossible to assess)
  3. History of mandibular fracture
  4. History of temporo-mandibular joint (TMJ) disorder
  5. Dentofacial dysmorphosis causing significant malocclusion
  6. Predictable inability to comply with the follow-up
  7. Unconsciousness / severe polytrauma
  8. Participation in another interventional study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Open (i.e. surgical) treatment

    This includes reduction and internal fixation of the fracture (ORIF) performed using the preferred surgical approach and bone implants of the including centre that could be associated with one or several items among the following: * physical therapy based on exercises done by the patient himself * physical therapy performed by a specialized/non-specialized physical therapist * arch bars / screws / splint use for transient MMF * arch bars / screws / splint use for passive mobilization of the mandible

    Procedure: Open treatment

  • Other
    Closed (i.e. conservative) treatment

    To date, there is no consensus on which procedures should be used in case of conservative treatment, which may vary between centres and, for a same centre, between patients. This includes one or several items among the following: * physical therapy based on exercises done by the patient himself * physical therapy performed by a specialized/non-specialized physical therapist * arch bars / screws / splint use for transient maxillo-mandibular fixation (MMF) (15 days max) * arch bars / screws / splint use for passive mobilization of the mandible

    Other: Closed treatment

Interventions

  • ProcedureOpen treatment

    Open (i.e. surgical) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.

    Also known as: Surgical treatment

  • OtherClosed treatment

    Closed (i.e. conservative) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.

    Also known as: Conservative treatment

06

What researchers measure

Primary outcomes

  1. Maximal mouth opening (in mm) at 3 months

    It will be obtained by measuring the interincisal distance at maximum mouth opening with a caliper or a ruler. The patient will be first asked to open the mouth as widely as possible for 3 seconds and to rest for 5 seconds. This sequence will be repeated 2 times and at the third repetition the patient will keep his/her mouth opened while the physician will measure inter-incisal distance

    Time frame: 3 months (+/-10 days)

Secondary outcomes

  1. Maximal mouth opening (in mm)

    Measured following the method described for primary outcome.

    Time frame: 3 weeks (+/- 7 days), 6 weeks (+/-7 days), 6 months (+/-20 days) and, 12 months (+/- 30 days) post-treatment

  2. Maximal mandibular protrusion (in mm)

    - Maximal mandibular protrusion in mm measured with a caliper or with a ruler, asking the patient to move the mandible as far as possible in the forward direction while keeping a slight contact between the dental arches. This measure will be done only after repetition of mouth opening and measurement of the maximum mouth opening, which will warm up mandibular mobilization

    Time frame: 3 weeks (+/- 7 days), 6 weeks (+/-7 days), 3 months (+/-10 days), 6 months (+/-20 days) and, 12 months (+/- 30 days) post-treatment

  3. Maximal lateral excursion (in mm)

    Maximal lateral excursion in mm measured with a caliper or with a ruler, asking the patient to move the mandible as far as possible in the right and left directions while keeping a slight contact between the dental arches. These measurements will be done only after repetition of mouth opening and measurement of the maximum mouth opening, which will warm up mandibular mobilization

    Time frame: 3 weeks (+/- 7 days), 6 weeks (+/-7 days), 3 months (+/-10 days), 6 months (+/-20 days) and, 12 months (+/- 30 days) post-treatment

  4. Lateral deviation of the mandible during mouth opening

    Lateral deviation of the mandible during mouth opening will be ranked as straight, right, or left. This observation can be made during the first measurement of mandibular opening

    Time frame: 3 weeks (+/- 7 days), 6 weeks (+/-7 days), 3 months (+/-10 days), 6 months (+/-20 days) and, 12 months (+/- 30 days) post-treatment

  5. Occlusal disturbance reported by the patient

    The patient will be asked to describe how his/her teeth touch as referring to his/her previous occlusion. He/she will rank his/her occlusion as: * not modified * slightly modified as compared to before the trauma but with no significant disturbance * significantly disturbed

    Time frame: 3 weeks (+/- 7 days), 6 weeks (+/-7 days), 3 months (+/-10 days), 6 months (+/-20 days) and, 12 months (+/- 30 days) post-treatment

  6. Occlusal disturbance evaluated by the surgeon

    The surgeon will ask the patient to bite and describe the occlusion as: * Not modified * Open bite: barely detectable (right / anterior / left) or clearly detectable (right / anterior / left) * Premature contact: barely detectable (right / anterior / left) or clearly detectable (right / anterior / left)

    Time frame: 3 weeks (+/- 7 days), 6 weeks (+/-7 days), 3 months (+/-10 days), 6 months (+/-20 days) and, 12 months (+/- 30 days) post-treatment

  7. Evaluation of pain using a visual analog scale

    The patient will be asked to rate his/her maximum pain in the last 2 days on a visual analog scale, 0 representing no pain and 10 representing the worst pain imaginable. For bilateral fractures, the pain will be assessed separately on each side.

    Time frame: 3 weeks (+/- 7 days), 6 weeks (+/-7 days), 3 months (+/-10 days), 6 months (+/-20 days) and, 12 months (+/- 30 days) post-treatment

  8. Subjective functional impairment evaluated by the patient using the Mandibular Function Impairment Questionnaire (MFIQ)

    The Mandibular Function Impairment Questionnaire (MFIQ) consisting in 17 items, rated between 0 and 4, which describes the difficulty in several common movement/activities involving the mandible (see questionnaire 1).

    Time frame: 3 weeks (+/- 7 days), 6 weeks (+/-7 days), 3 months (+/-10 days), 6 months (+/-20 days) and, 12 months (+/- 30 days) post-treatment

  9. Duration of sick leave

    Time frame: From treatment until 12 months

  10. Time to normal activity recovery

    Patient will asked on return to work and to normal daily activities (social activities, eating, sports)

    Time frame: Every week from week 1 to 6, every 2 weeks from week 8 to 12, and every month from month 4 to 12

  11. Compliance with the intervention - Number of appointments with a physical therapist

    The patient will fill in a notebook the number of appointments with a physical therapist since last patient report.

    Time frame: Every week from week 1 to 6, every 2 weeks from week 8 to 12, and every month from month 4 to 12

  12. Compliance with the intervention - Number of self-training sessions

    The patient will fill in a notebook the number of the number of self-training sessions since last patient report

    Time frame: Every week from week 1 to 6, every 2 weeks from week 8 to 12, and every month from month 4 to 12

  13. Compliance with the intervention - Duration of permanent MMF

    The patient will fill in a notebook the number of permanent MMF since last patient report

    Time frame: Every week from week 1 to 6, every 2 weeks from week 8 to 12, and every month from month 4 to 12

  14. Compliance with the intervention - Duration of transient MMF

    The duration of permanent MMF the duration of transient MMF since last patient report

    Time frame: Every week from week 1 to 6, every 2 weeks from week 8 to 12, and every month from month 4 to 12

  15. Compliance with the intervention - Duration of application of mobilization elastic band

    The patient will fill in a notebook the duration of application of mobilization elastic band.

    Time frame: Every week from week 1 to 6, every 2 weeks from week 8 to 12, and every month from month 4 to 12

  16. Compliance with the intervention - Average and Maximal pain

    The patient will fill in a notebook the average and maximal pain rate since last patient report

    Time frame: Every week from week 1 to 6, every 2 weeks from week 8 to 12, and every month from month 4 to 12

07

Study locations

1 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Aug 2026, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2021
First posted
Mar 1, 2021
StartActual
May 3, 2023
Primary completionEst.
Aug 2026
CompletionEst.
May 2027
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04776473
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
May 3, 2023
Primary completion
Aug 2026 (estimated)
Completion
May 2027 (estimated)
Last update
May 16, 2023

Study contacts

Thomas SCHOUMAN, MD
Contact
thomas.schouman@aphp.fr
(0)1 42 16 13 01 ext. +33
Mourad BENASSAROU, MD
Contact
mourad-azzedine.benassarou@aphp.fr
(0)1 42 16 13 01 ext. +33
Thomas SCHOUMAN, MD
principal investigator · AP-HP - Hôpital Pitié-Salpêtrière

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion